Double Digit NASDAQ Stock Winners: RCAT, PALT, KORS
7:38 am Tuesday, September 28th, 2021
Following are major stock gainers on Nasdaq in Monday’s trading session:
Red Cat Holdings, Inc. (NASDAQ:RCAT) was the active stock gainer on Monday and soared 50% to $3.960 as Red Cat Holdings Inc (NASDAQ: RCAT) subsidiary, Skypersonic, Inc, won a five-year contract from NASA to provide drone and rover software, hardware, and support for the Simulated Mars mission. The financial terms of the transaction remain undisclosed.
NASA’s crew would conduct simulated spacewalks and operations by remote piloting Skypersonic drones and rovers in a simulated Martian environment. Skypersonic’s Dronebox real-time transoceanic remote piloting platform will drive the piloting of both the drones and the rover.
Paltalk, Inc. (NASDAQ:PALT) stock surged 35% to $5.40. Paltalk, Inc., together with its subsidiaries, operates as a communications software provider that develops multimedia social applications and secure communication solutions worldwide. The company offers consumer applications, which include Paltalk, Camfrog, and Tinychat for live video chat; and Vumber, a telecommunications application that enables users to have multiple phone numbers in any area code through which calls can be forwarded to a user’s existing cell phone or land line telephone number.
It also provides technology development and related services; and professional services. The company was formerly known as PeerStream, Inc. and changed its name to Paltalk, Inc. in May 2020. Paltalk, Inc. is based in Jericho, New York.
Keros Therapeutics, Inc. (NASDAQ:KORS) moved up 32% to $43.71. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
